Progress on drug therapy of neuropathic pain

ZHAO Jiali; CHEN Qiuhong; LI Hongna; ZENG Lili; YE Yongxian; FEI Yan

doi:10.3969/j.issn.1006-0111.2016.04.006

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 34 Issue 4

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2016 > 34(4): 309-312

ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006

Citation:

ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006

Progress on drug therapy of neuropathic pain

doi: 10.3969/j.issn.1006-0111.2016.04.006

1.
Department of Pharmacy, No. 175 Hospital of PLA, Zhangzhou 363000, China
2.
Department of Orthopaedics, No. 175 Hospital of PLA, Zhangzhou 363000, China

Received Date: 2014-12-28
Rev Recd Date: 2016-01-08

Abstract

Neuropathic pain (NPP) is a chronic pain that caused by a series of infection and nerve damage events. It has high incidence, complex etiology and seriously affects patients' life quality. Although clinic trials gradually increased, the treatment of neuropathic pain is still insufficient. Recent research focuses on reasonably using drugs of different mechanisms and time of duration. The progress of NPP drugs was reviewed in this paper for providing basis for treatment of neuropathic pain.
- neuropathic pain,
- drug therapy,
- drug combination,
- targeting therapy

References

[1]	Attal N, Bouhassira D. Neuropathic pain:experimental advances and clinical applications[J]. Rev Neurol, 2004, 160(2):199-203.
[2]	Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain:the intersection of cancer pain and neuropathic pain[J]. Oncologist, 2010, 15(Suppl2):3-8.
[3]	Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain:involvement of inflammatory immune cells, immune-like glial cells and cytokines[J]. J Neuroimmunol, 2010, 229(1-2):26-50.
[4]	Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes:mechanisms of action and place in therapy[J]. Drugs, 2000, 60(5):1029-1052.
[5]	Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain[J]. Curr Pain Headache Rep, 2009, 13(3):185-190.
[6]	Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics:a review[J]. J Clin Pharmacol, 2012, 52(1):6-17.
[7]	Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline, in postherpetic neuralgia:a randomized, double-blind, crossover trial[J]. Pain, 1992, 48(1):29-36.
[8]	Jefferies K. Treatment of neuropathic pain[J]. Semin Neurol, 2010, 30(4):425-432.
[9]	Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision[J]. Eur J Neurol, 2010, 17(9):1113-1188.
[10]	Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009, 25(7):623-631.
[11]	Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain:systematic review of randomised trials[J]. BMC Neurol, 2008, 8:29.
[12]	Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain:consensus statement and guidelines from the Canadian Pain Society[J]. Pain Res Manag, 2007, 12(1):13-21.
[13]	Dooley DJ, Taylor CP, Donevan S, et al. Ca²⁺ channel α-2-δ ligands:novel modulators of neurotransmission[J]. Trends Pharmacol Sci, 2007, 28(2):75-82.
[14]	Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain:a randomized controlled trial from the Gabapentin Cancer Pain Study Group[J]. J Clin Oncol, 2004, 22(14):2909-2917.
[15]	Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuopathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trial of flexible-and fixed-dose regimens[J]. Pain, 2005, 115(3):254-263.
[16]	Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain:A double-blind, randomized controlled crossover trial[J]. Lancet, 2009, 374(9697):1252-1261.
[17]	Griggs RB, Bardo MT, Taylor BK. Gabapentin alleviates affective pain after traumatic nerve injury[J]. Neuroreport, 2015, 26(9):522-527.
[18]	Câmara CC, Araújo CV, de Sousa KKO, et al. Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats[J]. Neurosci Lett, 2015, 607:52-58.
[19]	Baillie JK, Power I. Morphine, gabapentin, or their combination for neuropathic pain[J]. N Engl J Med, 2005, 352(25):2650-2651.
[20]	García de Paredes ML, del Moral González F, Martínez del Prado P, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients results of oncology study[J]. Ann Oncol, 2011, 22(4):924-930.
[21]	Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy:a randomized, double-blind, controlled, trial. Pain, 1999, 83(1):85-90.
[22]	Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain:an overview and literature update[J]. Mayo Clin Proc,2010,85(3):S3-S14.
[23]	Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy[J]. Pain, 2001, 91(1-2):101-109.
[24]	Vadivelu N, Hines RL. Buprenorphine:a unique opioid with broad clinical applications[J]. J Opioid Manag, 2007, 3(1):49-58.
[25]	Vadivelu N, Hines RL. Management of chronic pain in the elderly:focus on transdermal buprenorphine[J]. Clin Interv Aging, 2008, 3(3):421-430.
[26]	Johnson RE, Fudala PJ, Payne R. Buprenorphine:considerations for pain management[J]. J Pain Symptom Manage, 2005, 29(3):297-326.
[27]	Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain[J]. J Pain, 2009, 10(2):113-130.
[28]	神经病理性疼痛诊疗专家组. 神经病理性疼痛诊疗专家共识[J]. 中国疼痛医学杂志,2013,19(12):705-710.
[29]	Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a change:optimizing communication and pain management decisions[J]. Curr Med Res Opin, 2011, 27(2):481-488.

Proportional views

通讯作者: 陈斌, [email protected]

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3856) PDF downloads(853) Cited by()

Proportional views

Progress on drug therapy of neuropathic pain

1. Department of Pharmacy, No. 175 Hospital of PLA, Zhangzhou 363000, China

2. Department of Orthopaedics, No. 175 Hospital of PLA, Zhangzhou 363000, China

Received Date: 2014-12-28

Rev Recd Date: 2016-01-08

Key words:

Abstract: Neuropathic pain (NPP) is a chronic pain that caused by a series of infection and nerve damage events. It has high incidence, complex etiology and seriously affects patients' life quality. Although clinic trials gradually increased, the treatment of neuropathic pain is still insufficient. Recent research focuses on reasonably using drugs of different mechanisms and time of duration. The progress of NPP drugs was reviewed in this paper for providing basis for treatment of neuropathic pain.

HTML

Reference (29)

[1]	Attal N, Bouhassira D. Neuropathic pain:experimental advances and clinical applications[J]. Rev Neurol, 2004, 160(2):199-203.
[2]	Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain:the intersection of cancer pain and neuropathic pain[J]. Oncologist, 2010, 15(Suppl2):3-8.
[3]	Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain:involvement of inflammatory immune cells, immune-like glial cells and cytokines[J]. J Neuroimmunol, 2010, 229(1-2):26-50.
[4]	Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes:mechanisms of action and place in therapy[J]. Drugs, 2000, 60(5):1029-1052.
[5]	Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain[J]. Curr Pain Headache Rep, 2009, 13(3):185-190.
[6]	Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics:a review[J]. J Clin Pharmacol, 2012, 52(1):6-17.
[7]	Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline, in postherpetic neuralgia:a randomized, double-blind, crossover trial[J]. Pain, 1992, 48(1):29-36.
[8]	Jefferies K. Treatment of neuropathic pain[J]. Semin Neurol, 2010, 30(4):425-432.
[9]	Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision[J]. Eur J Neurol, 2010, 17(9):1113-1188.
[10]	Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009, 25(7):623-631.
[11]	Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain:systematic review of randomised trials[J]. BMC Neurol, 2008, 8:29.
[12]	Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain:consensus statement and guidelines from the Canadian Pain Society[J]. Pain Res Manag, 2007, 12(1):13-21.
[13]	Dooley DJ, Taylor CP, Donevan S, et al. Ca²⁺ channel α-2-δ ligands:novel modulators of neurotransmission[J]. Trends Pharmacol Sci, 2007, 28(2):75-82.
[14]	Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain:a randomized controlled trial from the Gabapentin Cancer Pain Study Group[J]. J Clin Oncol, 2004, 22(14):2909-2917.
[15]	Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuopathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trial of flexible-and fixed-dose regimens[J]. Pain, 2005, 115(3):254-263.
[16]	Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain:A double-blind, randomized controlled crossover trial[J]. Lancet, 2009, 374(9697):1252-1261.
[17]	Griggs RB, Bardo MT, Taylor BK. Gabapentin alleviates affective pain after traumatic nerve injury[J]. Neuroreport, 2015, 26(9):522-527.
[18]	Câmara CC, Araújo CV, de Sousa KKO, et al. Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats[J]. Neurosci Lett, 2015, 607:52-58.
[19]	Baillie JK, Power I. Morphine, gabapentin, or their combination for neuropathic pain[J]. N Engl J Med, 2005, 352(25):2650-2651.
[20]	García de Paredes ML, del Moral González F, Martínez del Prado P, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients results of oncology study[J]. Ann Oncol, 2011, 22(4):924-930.
[21]	Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy:a randomized, double-blind, controlled, trial. Pain, 1999, 83(1):85-90.
[22]	Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain:an overview and literature update[J]. Mayo Clin Proc,2010,85(3):S3-S14.
[23]	Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy[J]. Pain, 2001, 91(1-2):101-109.
[24]	Vadivelu N, Hines RL. Buprenorphine:a unique opioid with broad clinical applications[J]. J Opioid Manag, 2007, 3(1):49-58.
[25]	Vadivelu N, Hines RL. Management of chronic pain in the elderly:focus on transdermal buprenorphine[J]. Clin Interv Aging, 2008, 3(3):421-430.
[26]	Johnson RE, Fudala PJ, Payne R. Buprenorphine:considerations for pain management[J]. J Pain Symptom Manage, 2005, 29(3):297-326.
[27]	Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain[J]. J Pain, 2009, 10(2):113-130.
[28]	神经病理性疼痛诊疗专家组. 神经病理性疼痛诊疗专家共识[J]. 中国疼痛医学杂志,2013,19(12):705-710.
[29]	Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a change:optimizing communication and pain management decisions[J]. Curr Med Res Opin, 2011, 27(2):481-488.

Message Board

Progress on drug therapy of neuropathic pain

doi: 10.3969/j.issn.1006-0111.2016.04.006

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views